![Ian A. Critchley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ian A. Critchley
Corporate Officer/Principal chez SPERO THERAPEUTICS, INC.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Ankit Mahadevia | M | 43 | 11 ans | |
Satyavrat Shukla | M | 52 | 3 ans | |
Milind Deshpande | M | 67 | 10 ans | |
Frank Thomas | M | 54 | 7 ans | |
John Pottage | M | 71 | 6 ans | |
Scott Jackson | M | 59 | 4 ans | |
Patrick Volkert Vink | M | 60 | 9 ans | |
Cynthia Smith | F | 55 | 5 ans | |
Timothy Keutzer | M | 56 | - | |
Kathleen Tregoning | F | 53 | 3 ans | |
Esther Rajavelu | F | 46 | 1 ans | |
Angela Talley | M | - | - | |
James P. Brady | M | - | - | |
Alex Thurman | M | 54 | 8 ans | |
Kamal Hamed | M | 63 | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Scott Giacobello | M | 54 | 7 ans | |
David Adam Buchen | M | 59 | 1 ans | |
Andrew L. Turner | M | 77 | 2 ans | |
Hafrun Fridriksdottir | M | 62 | 14 ans | |
David Hovland | M | - | 8 ans | |
Roger J. Lias | M | 63 | 6 ans | |
Joseph H. Boccuzi | M | 77 | 3 ans | |
Peter John McDonnell | M | 66 | 5 ans | |
John A. King | M | 74 | 2 ans | |
Dirk Thye | M | 54 |
Cerexa, Inc.
![]() Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 6 ans |
Daphne Karydas | F | 49 | 3 ans | |
Jirí Michal | M | 71 | 2 ans | |
Jason A. Leverone | M | 50 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 ans |
Tamar Howson | F | 75 | 9 ans | |
Adriane Brown | M | 65 | 3 ans | |
Michael R. Gallagher | M | 77 | 2 ans | |
Mark L. Smith | M | 72 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 ans |
Kevin Krause | M | 49 |
Cerexa, Inc.
![]() Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 4 ans |
Cornelia Haag-Molkenteller | M | 66 | 11 ans | |
Sue-Jean Lin | F | 65 | 26 ans | |
Megan Schoeps | F | 40 | 2 ans | |
Matthew Walsh | M | 57 | 2 ans | |
David Melnick | M | 72 | - | |
Herm Cukier | M | 57 | 5 ans | |
Yao Lee | M | 54 | 4 ans | |
Carmen Betancourt | F | - |
Cerexa, Inc.
![]() Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 1 ans |
Nori Ebersole | F | 60 | 18 ans | |
Kirk Calhoun | M | 80 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 ans |
David Bharucha | M | 62 | 4 ans | |
Jonathan Garen | M | 58 | - | |
Daniel Motto | M | - | 6 ans | |
Carlos Campoy | M | 60 | 2 ans | |
Todd Branning | M | 54 | 3 ans | |
Sailaja Puttagunta | M | 55 | 1 ans | |
Dwight Moxie | M | 48 | 5 ans | |
Kathleen Reape | M | 58 | 1 ans | |
Matthew Moore | M | 51 | 5 ans | |
Kathryn DiMarco | F | 57 | 5 ans | |
Karah Parschauer | F | 46 | 11 ans | |
Robert Stewart | M | 56 | 9 ans | |
Sanjiv Patel | M | 50 | 11 ans | |
Christopher D. Earl | M | 68 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 4 ans |
Edward Brown | M | 61 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 2 ans |
Roger M. Echols | M | 75 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 ans |
Peter W. Letebdre | M | - |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
Chris Christoffersen | M | 86 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
Laurent Fischer | M | 60 | 4 ans | |
Barbara E. Baring | F | - |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 2 ans |
Maria Hilado | F | 60 | 4 ans | |
Richard Spivey | M | 74 | 5 ans | |
Geoff Duyk | M | 64 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 5 ans |
Michael Rowe | M | 62 | 6 ans | |
Paul Grint | M | 66 |
Cerexa, Inc.
![]() Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 3 ans |
Pamela Vig | M | 53 | - | |
Leonard Dove | M | 51 | 2 ans | |
Michael Dunne | M | 64 | 1 ans | |
Bryan Smith | M | 45 | 7 ans | |
Charles M. Mayr | M | 67 | 3 ans | |
Peter W. Letendre | M | 66 |
Replidyne, Inc.
![]() Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 ans |
Paul Navarre | M | - | - | |
Eric Lefebvre | M | 60 | 2 ans | |
Lisa M. DeFrancesco | F | 45 | - | |
Carolyn Myers | M | 66 | 6 ans | |
Thomas Nee | M | - | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Irlande | 50 | 63,29% |
Etats-Unis | 29 | 36,71% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Ian A. Critchley
- Réseau Personnel